

MARKSANS PHARMA LIMITED [formerly Tasc Pharmaceuticals Ltd.]

Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd. A.K.Road, Andheri [East], Mumbai-400099

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2005

Sr. No.	PARTICULARS	Quarter ended		six months ended		(Rs. In lacs)
		30th Sept. 05 (UNAUDITED)	30th Sept. 04 (UNAUDITED)	30th Sept. 05 (UNAUDITED)	30th Sept. 04 (UNAUDITED)	31st March 05 (AUDITED)
1	Net sales /Income from Operations	8,984.40	5,339.11	17,474.17	10,194.26	25,289.56
2	Other Income	39.84	23.27	79.83	75.77	163.65
3	Total Expenditure	7,299.26	4,381.80	14,220.79	8,281.34	21,059.89
	-(Increase) /Decrease in Stock in trade	(142.19)	(412.83)	574.95	(117.00)	(1,522.46)
	-Consumption of Raw Material	6,294.15	3,701.89	11,428.54	6,518.67	18,647.40
	-Staff Cost	160.38	179.14	353.40	348.46	723.16
	-Other Expenditure	986.92	913.60	1,863.90	1,531.21	3,211.79
4	Interest	265.06	245.48	587.62	573.13	1,191.55
5	Depreciation	378.08	161.18	553.54	316.59	694.99
6	Profit/(Loss) before Tax	1,081.84	573.92	2,192.05	1,098.97	2,506.78
7	Provision for Taxation					
	a) Current	44.18	105.30	151.91	105.30	236.25
	b) Deferred	0.00	0.00	0.00		214.68
8	Net Profit /(Loss)	1,037.66	468.62	2,040.14	993.67	2,055.85
9	Add/Less :Short provision/ Prior period expenses	0.00	0.00	0.00	0.00	0.00
10	Net Profit/(after extra ordinary items)	1,037.66	468.62	2,040.14	993.67	2,055.85
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus (Excluding Revaluation Reserve)	-	-	-	-	5,286.46
13	Basic and Diluted EPS for the period (Not annualised)	2.89	1.30	5.68	2.76	5.72
14	Non -Promoter share holding					
	-Number of Shares	18340527	4606100	18340527	4606100	8738000
	-Percentage of Share holding	51.03%	46.06%	51.03%	46.06%	69.90%

Notes:

- The above results were taken on records at the Board meeting held on 29-10-2005
- Pursuant to the scheme of amalgamation sanctioned by the Hon'ble High Court at Mumbai on 19.08.05, the assets & liabilities of the erstwhile Glenmark Laboratories Ltd. were transferred to and vested in the company with retrospective effect from 01.04.04
- Pursuant to the scheme referred to at (2) above, 2,34,40,563 Equity shares of Rs.10/- each and 13,50,000 7% Redeemable Cumulative Preference Shares of Rs.100/- each are issued to the shareholders of erstwhile Glenmark Laboratories Ltd. These shares were allotted on 18.10.05
- The company has successfully raised USD 50 million through Zero Coupon Foreign Currency Convertible Bonds issue.
- EPS has been calculated on the basis of total number of equity shares of the amalgamated entity [including shares issued pursuant to amalgamation]. EPS is not annualised.
- The details of investor complaints during the quarter is as under:
Opening Balance : NIL, Received during the quarter : 20, Pending as on 30.09.05 : NIL
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Previous year's figures also include the consolidated figures of the amalgamated entity and have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai

Date: 29th October, 2005

For Marksans Pharma Limited

Mark Saldanha
Managing Director